Eri Miyata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eri Miyata has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Shimizu
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
3 shared publications - Hirotaka Shimizu
Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications - Ichiro Takeuchi
Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications - Katsuhiro Arai
Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan
2 shared publications - Keisuke Jimbo
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
2 shared publications - Masanori Toda
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 492-503
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
- 12 December 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 492-503
Open AccessFecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
- 4 November 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (1) , 123-132
Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure
Background and Aim: Only a few studies have reported the long‐term effects of ustekinumab on pediatric Crohn's disease. Therefore, this study aimed to describe the long‐term clinical and endoscopic outcomes of ustekinumab and its safety profile in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure. Methods: Medical records of patients with pediatric‐onset Crohn's disease in whom anti‐tumor necrosis factor therapy failed and ustekinumab treatment was initiated from 2017 to 2022 at a Japanese tertiary children's hospital were retrospectively reviewed. The primary outcome was the continuation rates at weeks 8, 52, and 106. The secondary outcomes were the steroid‐free remission rates at weeks 8, 52, and 106, changes in the Simple Endoscopic Score for Crohn's Disease, and adverse events during follow‐up. Results: Forty‐three patients were enrolled. The median ages at diagnosis and ustekinumab introduction were 9.7 (interquartile range: 6.7–13.0) years and 13.6 (interquartile range: 8.0–16.0) years. The median follow‐up period was 136 (interquartile range: 102–172) weeks. The continuation rates were 100%, 91%, and 80% at weeks 8, 52, and 106, respectively. The incidence of discontinuation was 6.2% per patient‐year of follow‐up. The steroid‐free remission rates were 44%, 71%, and 80% at weeks 8, 52, and 106, respectively. The Simple Endoscopic Score for Crohn's Disease of patients in clinical remission at the last follow‐up significantly decreased ( P < 0.01), and the safety profile was acceptable. Conclusions: Ustekinumab appeared effective in maintaining long‐term clinical remission with endoscopic improvement in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure.
- 4 November 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (1) , 123-132
Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure
Background and Aim: Only a few studies have reported the long‐term effects of ustekinumab on pediatric Crohn's disease. Therefore, this study aimed to describe the long‐term clinical and endoscopic outcomes of ustekinumab and its safety profile in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure. Methods: Medical records of patients with pediatric‐onset Crohn's disease in whom anti‐tumor necrosis factor therapy failed and ustekinumab treatment was initiated from 2017 to 2022 at a Japanese tertiary children's hospital were retrospectively reviewed. The primary outcome was the continuation rates at weeks 8, 52, and 106. The secondary outcomes were the steroid‐free remission rates at weeks 8, 52, and 106, changes in the Simple Endoscopic Score for Crohn's Disease, and adverse events during follow‐up. Results: Forty‐three patients were enrolled. The median ages at diagnosis and ustekinumab introduction were 9.7 (interquartile range: 6.7–13.0) years and 13.6 (interquartile range: 8.0–16.0) years. The median follow‐up period was 136 (interquartile range: 102–172) weeks. The continuation rates were 100%, 91%, and 80% at weeks 8, 52, and 106, respectively. The incidence of discontinuation was 6.2% per patient‐year of follow‐up. The steroid‐free remission rates were 44%, 71%, and 80% at weeks 8, 52, and 106, respectively. The Simple Endoscopic Score for Crohn's Disease of patients in clinical remission at the last follow‐up significantly decreased ( P < 0.01), and the safety profile was acceptable. Conclusions: Ustekinumab appeared effective in maintaining long‐term clinical remission with endoscopic improvement in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15551
Refractory pediatric ulcerative colitis responding to high dose tofacitinib
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15551
Refractory pediatric ulcerative colitis responding to high dose tofacitinib
- 18 October 2020
- Published by Wiley in Helicobacter
- Vol. 26 (1) , e12764
Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years
Background: Helicobacter pylori (H. pylori) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori‐positive children who underwent EGD over a 12‐year period.Materials and Methods: The subjects were H. pylori‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy.Results: Forty‐five patients were H. pylori‐positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, we prescribed effective antibiotics, and this resulted in a primary eradication rate of 97.7%.Conclusions: We suggest that antimicrobial susceptibility testing can significantly improve rates of primary eradication of H. pylori infection.
- 18 October 2020
- Published by Wiley in Helicobacter
- Vol. 26 (1) , e12764
Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years
Background: Helicobacter pylori (H. pylori) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori‐positive children who underwent EGD over a 12‐year period.Materials and Methods: The subjects were H. pylori‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy.Results: Forty‐five patients were H. pylori‐positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, we prescribed effective antibiotics, and this resulted in a primary eradication rate of 97.7%.Conclusions: We suggest that antimicrobial susceptibility testing can significantly improve rates of primary eradication of H. pylori infection.
- Open Access
- 1 November 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (5) , 725-731
Differential cell division history between neutrophils and macrophages in their development from granulocyte–macrophage progenitors
The appearance of monocytes before neutrophils in the blood during haematopoietic recovery in myelosuppressive patients is commonly observed, thus suggesting a difference in the cell division history between these two lineages in the differentiation from granulocyte–macrophage (GM) progenitors. We investigated the cell division histories of murine GM progenitors. When analysed by the dye dilution method, GM progenitors gave rise to Gr‐1+Fms+ and Gr‐1+Fms− cells that passed through similar rounds of cell division during initial 5 d of culture. The Gr‐1+Fms+ cells showed morphological features of monocytes, while Gr‐1+Fms− cells exhibited an immature morphology of neutrophils. In the subsequent culture, a decline in the number of Gr‐1+Fms+ cells was observed, while Gr‐1+Fms− cells increased. The proliferation of Gr‐1+Fms− cells and no cell division of Gr‐1+Fms+ cells were confirmed by DNA staining, Ki‐67 expression, membrane dye staining and bromodeoxyuridine incorporation. These Gr‐1+Fms− cells acquired mature neutrophil morphology, whereas Gr‐1+Fms+ cells became macrophages. These results demonstrate that GM progenitors generate postmitotic monocytes earlier than mature neutrophils. Our data may also offer one explanation for the rapid recovery of monocytes in comparison with neutrophils in the early phase of haematopoietic regeneration.
- 1 November 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (5) , 725-731
Open AccessDifferential cell division history between neutrophils and macrophages in their development from granulocyte–macrophage progenitors
The appearance of monocytes before neutrophils in the blood during haematopoietic recovery in myelosuppressive patients is commonly observed, thus suggesting a difference in the cell division history between these two lineages in the differentiation from granulocyte–macrophage (GM) progenitors. We investigated the cell division histories of murine GM progenitors. When analysed by the dye dilution method, GM progenitors gave rise to Gr‐1+Fms+ and Gr‐1+Fms− cells that passed through similar rounds of cell division during initial 5 d of culture. The Gr‐1+Fms+ cells showed morphological features of monocytes, while Gr‐1+Fms− cells exhibited an immature morphology of neutrophils. In the subsequent culture, a decline in the number of Gr‐1+Fms+ cells was observed, while Gr‐1+Fms− cells increased. The proliferation of Gr‐1+Fms− cells and no cell division of Gr‐1+Fms+ cells were confirmed by DNA staining, Ki‐67 expression, membrane dye staining and bromodeoxyuridine incorporation. These Gr‐1+Fms− cells acquired mature neutrophil morphology, whereas Gr‐1+Fms+ cells became macrophages. These results demonstrate that GM progenitors generate postmitotic monocytes earlier than mature neutrophils. Our data may also offer one explanation for the rapid recovery of monocytes in comparison with neutrophils in the early phase of haematopoietic regeneration.